Inspire Medical: A 14% Pop Masks an 80% Decline — Is the Coding Crisis Resolving?

Inspire Medical Systems (NYSE: INSP) shares jumped roughly 14% after the company reported Q2 2026 results that beat consensus on both revenue and earnings, while lifting full-year guidance on both metrics.

I've been puzzled by the reaction. The stock had already been down 80% from its peak over the past three years, getting battered by sequential guidance cuts that left investors wondering whether the obstructive sleep apnea implant franchise was falling apart. Now the market is celebrating a modest mid-range guidance tweak and a quarter where revenue actually fell 7.6% year-over-year.

Here's what the market is missing: the guidance raise is real, the coding disruption appears to be peaking, and the valuation disconnect between where the stock trades and where it should is arguably as wide as it's ever been. But the recent pop complicates the entry picture.

The Quarter: Better Than Feared, But Revenue Still Shrunk

Inspire generated $200.6 million in Q2 revenue, down 7.6% from the same quarter last year, but above the $194.7 million consensus. GAAP diluted EPS came in at $0.01. Adjusted diluted EPS was $0.14, beating the analyst consensus estimate of -$0.27 — a $0.41 swing that flipped the quarter from an expected loss to a profit.

Revenue declined because of the ongoing U.S. reimbursement coding disruption — more on that below — though international revenue growth partially offset the domestic drag. The good news is in the operating mechanics: gross margin expanded 150 basis points to 85.5%, driven by the higher-margin Inspire V system taking a larger share of the mix. Operating expenses fell $13.8 million (7.4%), reflecting lower stock-based compensation and marketing spend. Operating cash flow was $23.2 million for the quarter.

The company also announced a strategic growth plan designed to unlock approximately $30 million in annualized cost savings for redeployment into growth initiatives. That's not a restructuring program in the layoffs-and-shutdown sense; it's a capital reallocation signal that management is actively working to improve the return profile.

The Guidance Raise: Modest But Directionally Positive

The company lifted its full-year 2026 revenue guidance from $825 million–$875 million to $835 million–$875 million. The midpoint is $855 million. That's a $10 million bump to the low end, which isn't dramatic.

More meaningful is the adjusted EPS guidance raise, from $0.75–$1.25 to $1.05–$1.45. That represents a 40% lift to the low end and a 16% lift to the high end. The earnings improvement comes from both the cost discipline evident in Q2 and the expectation that the coding disruption, which has weighed on physician adoption and revenue recognition timing, is beginning to stabilize.

Put the guidance in context and the picture becomes clearer. In February, when Inspire reported full-year 2025 results, it guided to $950 million–$1 billion for 2026. By Q1, that was slashed to $825 million–$875 million. The Q2 raise doesn't reverse the decline — 2026 revenue is still expected to be down 4% to 10% from the $912 million reported in 2025 — but it signals the trough is approaching.

The Real Story: CPT Coding Chaos

The root cause of Inspire's 2026 revenue decline is a reimbursement coding change that the market has misread as structural damage. The Inspire V procedure transitioned to CPT code 64582 with a -52 modifier (indicating reduced services), which reduces physician reimbursement fees compared to the previous code. CEO Tim Herbert called the outcome disappointing. The company is actively pursuing a separate, dedicated CPT code to support appropriate reimbursement.

What matters is the duration. Management expects the disruption to persist through the balance of 2026 but has characterized it as temporary, projecting revenue between $1.003 billion and $1.013 billion for 2027 — representing 10%–11% growth. The -52 modifier is not a coverage denial or a Medicare retreat from hypoglossal nerve stimulation; Medicare's local coverage determination for the therapy remains in place. It's a billing mechanics problem, and billing mechanics problems tend to resolve because everyone — including the physicians whose fees are being cut — has an incentive to fix them.

The Moat Survives the Mess

Before calling this a contrarian opportunity, the competitive position needs to hold up under the stress. Inspire's moat in hypoglossal nerve stimulation (the surgical implantation of a device that stimulates the tongue nerve to keep the airway open during sleep) remains intact. The company has no peer with comparable scale, center network, or FDA-clearance depth in the U.S. market. The PREDICTOR study published earlier this year strengthened the clinical evidence base. Nyxoah, the closest European competitor, is actually a defendant in a patent infringement suit filed by Inspire.

The gross margin expansion to 85.5% — despite a shrinking revenue base — is a stress test that the moat passed. If reimbursement pressure were cracking the business model's core economics, margins would be collapsing. They aren't. They're expanding.

Valuation: The Disconnect Is the Setup

This is where the bull case turns from defensible to compelling. Inspire stock trades at roughly 11 times earnings — down from forward multiples that exceeded 50x not long ago. The wider medical equipment industry averages approximately 26 to 30 times earnings. Third-party fair P/E estimates sit around 15.2 to 16.2 times, and DCF intrinsic value models point to roughly $56 per share. The stock is trading at a discount across every major valuation benchmark.

A company growing the sleep apnea implant market, operating at 85%+ gross margins, with a projected return to double-digit revenue growth in 2027, should not be trading at 11x earnings. The market has baked in a narrative that the coding problem is permanent or that Inspire's revenue can never recover its trajectory. The numbers don't support that story.

The Entry Problem

I don't think investors need to chase the post-earnings rally. The stock popped 14% and then sold off, closing near $49 on August 6th after hitting $59.85 in pre-market trading on the news. That kind of whipsaw action tells you the market is still nervous — which is actually supportive of the contrarian case, but it also means timing matters.

The setup here is a Buy, but the better risk/reward is likely on weakness. If the stock can retest the $45–$47 area where it had been trading for months before the earnings release, that's a much cleaner entry. The fundamental thesis — coding disruption is temporary, moat is intact, margins are expanding, 2027 growth is loaded — doesn't change because the stock bounced 14% for one afternoon.

Investors awaiting an opportunity to add exposure to a battered medtech franchise at distressed multiples shouldn't let this setup go to waste. But patience on entry is part of the edge here too. Double down on weakness, don't chase the pop.

I would reassess this view if 2027 guidance fails to materialize — specifically if Inspire reports at Q4 that the -52 modifier has structurally impaired adoption or if the gross margin advantage begins to erode. Until then, the market's 80% verdict on Inspire appears overdone.